European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. MSFT
5. ACN
6. FFAI
7. PAGP
8. WBD
9. FAN
10. COHR

Go back to European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
(AMEX: MKKGY) Delayed: 29.75 --0 (-0%)
Previous Close $29.75    52 Week High $ 
Open $29.75    52 Week Low $ 
Day High $29.75    P/E N/A 
Day Low $29.75    EPS $ 
Volume 4       

Merck & Co. (NYSE: MRK) Delayed: 146.87 --0 (-0%)
Previous Close $146.87    52 Week High $65.46 
Open $146.87    52 Week Low $47.97 
Day High $146.87    P/E 99.91 
Day Low $146.87    EPS $1.47 
Volume 10,842       

Pfizer Inc. (NYSE: PFE) Delayed: 27.66 --0 (-0%)
Previous Close $27.66    52 Week High $37.39 
Open $27.66    52 Week Low $28.25 
Day High $27.66    P/E 16.76 
Day Low $27.66    EPS $1.65 
Volume 67,586